期刊
CANCERS
卷 11, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/cancers11020148
关键词
cancer; HDI; HDAC; EMT; MET; cadherin; catenin; vimentin; migration; invasion
类别
资金
- Medical University of Lublin [DS440/2018-2019]
- Polish Ministry of Science and Higher Education [MNmb 402/2018-2019, MNmb 510/2016-2017]
- Polish National Science Centre (NCN) [DEC-2015/17/B/NZ1/01777, DEC-2017/25/B/NZ4/02364]
Histone deacetylase inhibitors (HDIs) are a group of potent epigenetic drugs which have been investigated for their therapeutic potential in various clinical disorders, including hematological malignancies and solid tumors. Currently, several HDIs are already in clinical use and many more are on clinical trials. HDIs have shown efficacy to inhibit initiation and progression of cancer cells. Nevertheless, both pro-invasive and anti-invasive activities of HDIs have been reported, questioning their impact in carcinogenesis. The aim of this review is to compile and discuss the most recent findings on the effect of HDIs on the epithelial-mesenchymal transition (EMT) process in human cancers. We have summarized the impact of HDIs on epithelial (E-cadherin, beta-catenin) and mesenchymal (N-cadherin, vimentin) markers, EMT activators (TWIST, SNAIL, SLUG, SMAD, ZEB), as well as morphology, migration and invasion potential of cancer cells. We further discuss the use of HDIs as monotherapy or in combination with existing or novel anti-neoplastic drugs in relation to changes in EMT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据